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Physiology and Biochemistry, University of Malta, Msida, MaltaABSTRACT Aggregation of a-synuclein is involved in the pathogenesis of Parkinson’s disease (PD). Studies of in vitro
aggregation of a-synuclein are rendered complex because of the formation of a heterogeneous population of oligomers. With
the use of confocal single-molecule fluorescence techniques, we demonstrate that small aggregates (oligomers) of a-synuclein
formed from unbound monomeric species in the presence of organic solvent (DMSO) and iron (Fe3þ) ions have a high affinity to
bind to model membranes, regardless of the lipid-composition or membrane curvature. This binding mode contrasts with the
well-established membrane binding of a-synuclein monomers, which is accompanied with a-helix formation and requires
membranes with high curvature, defects in the lipid packing, and/or negatively charged lipids. Additionally, we demonstrate
that membrane-bound a-synuclein monomers are protected from aggregation. Finally, we identified compounds that potently
dissolved vesicle-bound a-synuclein oligomers into monomers, leaving the lipid vesicles intact. As it is commonly believed
that formation of oligomers is related PD progression, such compounds may provide a promising strategy for the design of novel
therapeutic drugs in Parkinson’s disease.INTRODUCTIONAggregation and amyloid formation of disease-specific
proteins are key events in a number of neurodegenerative
disorders such as Alzheimer’s disease and Parkinson’s
disease (PD) (1,2). A common feature of the aggregation
cascade is the formation of oligomeric species that eventu-
ally mature to form larger insoluble deposits. Several find-
ings suggest that oligomeric intermediates, rather than
mature amyloid fibrils, represent the principal neurotoxic
aggregate species (2–8). A characteristic feature of PD is
the intracellular deposition of Lewy bodies in which
a-synuclein (aS) represents the major protein component
(9). This 140-amino-acid protein is widely distributed
throughout the brain (10). A remarkable property of aS
is its structural flexibility. In dilute aqueous solutions,
the protein is essentially unstructured, whereas it adopts
a-helical structure upon binding to lipids (11). In contrast,
misfolding leads to formation of ordered fibrils with a rigid
b-sheet-like structure both in vitro (12,13) and in vivo in
Lewy bodies (14). Aggregation of aS also involves the
formation of cytotoxic oligomeric assemblies (14–18).
The biophysical and functional properties of these disease-
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. Open access under CC BY-NC-ND license.of oligomer toxicity that has been proposed is the forma-
tion of pores that lead to permeabilization of cellular
membranes (5,7,19–23). Metal ions trigger the generation
of oligomeric species and accelerate the formation of
amyloid aS fibrils (4,13,24,25). Several lines of evidence
indicate that particularly iron plays an important role in
PD pathogenesis. In vitro, association of aS monomers
with iron ions has also been reported (13,26,27). Iron ex-
posure has been shown to increase PD risk in epidemiolog-
ical studies (28,29), increased iron levels correlate with
the severity of neuropathological changes in PD patients
(30), and high levels of Fe3þ have been found in Lewy
bodies (31).
When monomeric aS binds to a lipid-water interface,
the N-terminus acquires a helical structure whereas
the C-terminus remains unstructured (5,11,32). This lipid-
binding mode has been analyzed in vitro by various
biophysical techniques (33–38). The affinity of aS to mem-
branes depends on curvature and lipid composition, i.e., aS
binds with high affinity to membranes with negative charge
and high curvature (5,32,39–41). aS also binds to small
unilamellar vesicles (SUVs) of zwitterionic lipids in the
gel-phase (DPPC, below chain-melting temperature, Tm)
(5,33,34,42). On the other hand, aS has a low affinity to
bind to SUVs of zwitterionic lipids in the liquid-crystalline
phase (such as POPC) (43,44). Furthermore, binding of aS
depends on defect structures present in ordered membranes
of high curvature. In stressed membranes, aS is capable of
annealing defects, hence preventing membranes from fusion
(33,34,45). The membrane affinity and concomitant struc-
tural transition of aS led to the assumption that binding ofdoi: 10.1016/j.bpj.2012.01.059
FCS Study of Lipid Binding by Synuclein 1647aS monomers to synaptic vesicles is related to its physio-
logical role at synaptic nerve terminals (5,14,46–48). Asso-
ciation of aS to mitochondria has also been described
(45,49,50).
With regard to structural studies on the formation of olig-
omeric assemblies, the most common techniques include
immunoblotting, electron microscopy, nuclear magnetic
resonance, electron spin resonance, atomic force micros-
copy, and size-exclusion chromatography. In addition,
confocal single-particle fluorescence spectroscopy tech-
niques have been developed to analyze aggregation of
proteins (51–56). Using these techniques, we could charac-
terize two different aS oligomer species that were both on-
pathway to amyloid fibrils. Organic solvents (ethanol or
dimethyl sulfoxide (DMSO)) triggered aggregation result-
ing in the formation of small (i.e., intermediate-I) oligomers
(4). Subsequent addition of Fe3þ ions close to physiological
serum levels (5–20 mM) induced formation of larger
oligomer species (i.e., intermediate-II). The latter species
are SDS-resistant, form ion-permeable pores in a planar
lipid bilayer system (4), and are toxic in neuronal cell
cultures (57). These findings go along with several
lines of evidence implicating the involvement of Fe3þ
iron in disease progression in PD, as mentioned above
(13,24,26,58,59).
The aim of this study was to improve the understanding
of the molecular pathophysiology of the aS aggregation
processes in PD. In light of the well-reported binding
mode of monomeric aS to lipid membranes, we evaluated
the iron-induced formation of aS oligomers in the presence
of model lipid vesicles using fluorescence intensity dis-
tribution analyses (FIDA) for qualitative and quantitative
evaluation of the heterogeneous population of oligomers
that is usually formed in in vitro aggregation assays. By
labeling aS and vesicles with a different color, the interac-
tion between aS and vesicles was measured. In particular,
we were interested to investigate 1), whether the direct in-
teraction of monomeric aS with lipid vesicles of varying
phospholipid composition would influence iron-induced
oligomer formation, 2), whether aS aggregation results in
oligomers with different properties in regard to membrane
binding compared to aS monomers, and 3), whether this
approach can be used as a model system for characterization
of compounds blocking aS aggregation in regard to their
effects on physiological and pathological interaction of aS
with lipid membranes.MATERIALS AND METHODS
Chemicals
Phospholipids (1-palmityl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
and dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) were purchased
from Avanti Polar Lipids (Alabaster, AL). BODIPY-FL-DHPE (BODIPY-
PE) and Alexa Fluor-647-O-succinimidylester were from Invitrogen
(Carlsbad, CA).Purification and labeling of recombinant
wild type aS
Expression and purification was performed as described previously (34).
Protein labeling was performed with the amino-reactive fluorescent dye
Alexa Fluor-647-O-succinimidylester (‘‘red’’) as described previously (4).Vesicle preparation
A green fluorescent dye was incorporated into the vesicles by mixing 0.1%
(w/w) BODIPY-PE with the lipids (POPC or DPPC) in chloroform.
Chloroform was evaporated with nitrogen gas and 1 h vacuum. Buffer
was added to the lipid film, which was vortexed and then hydrated for at
least 1 h. Large unilamellar vesicles (LUVs) were made by extrusion,
and small unilamellar vesicles (SUVs) were made by sonication as
described in Kamp et al. (60). The size of the vesicles was checked with
dynamic light scattering measurements using a High Performance Particles
Sizer (Malvern Instruments, Herrenberg, Germany). SUVs and LUVs
usually had a diameter of 25–35 nm and 70–80 nm, respectively. Vesicles
were diluted to a final lipid concentration of 100 mM and stored at 4C.Aggregation assay
Experiments were started by diluting the stock solution of aS-647, pH 7.0,
in a total assay volume of 20 mL. The concentration of aS-647 was adjusted
to ~10 molecules per focal volume, (z10 nM). Vesicles were added at
a final lipid concentration of 10 mM. To induce aS oligomerization we
added either 10 mM FeCl3, DMSO (1% v/v), or DMSO (1% v/v)
plus 10 mM FeCl3, respectively. All experiments were performed in
96-well-plates (Evotec-Technologies, Hamburg, Germany). At least five
measurements were performed and averaged after 2 h of incubation in
two-to-four independent wells per experimental group.Confocal single particle analysis
Fluorescence correlation spectroscopy (FCS) and scanning for intensely
fluorescent targets (SIFT) measurements were carried out on an Insight
Reader (Evotec-Technologies) with dual color excitation at 488 and
633 nm as described before (4). Measurement time was 10 s for SIFT
measurements and 300 s for FCS measurements. For fluorescence intensity
distribution analysis (FIDA), fluorescence from the two different fluoro-
phores was recorded simultaneously. Photons were summed over time inter-
vals of constant length (bins) using a bin length of 40 ms (i.e., 5  10 s
measurement time generates 1,250,000 bins). All measurements were
performed at room temperature.RESULTS
Quantitative analysis of lipid binding of aS with
confocal single particle fluorescence techniques
Weused SUVs of zwitterionic lipids in the gel-phase (DPPC-
SUV) for the first set of binding studies, in light of the re-
ported strong association of aS to these vesicles (34). To
evaluate protein aggregation and lipid binding we always
used red-labeled aS (aS-647) and green-labeled vesicles.
Fig. 1 A shows 2D-FIDA histograms acquired from SIFT
measurements of aS alone, DPPC-SUValone, and a mixture
of aS and DPPC-SUV, respectively. FIDA histograms depict
the distribution of the amount of photons that were detected
within the bin length (40 ms) of the SIFT measurements, notBiophysical Journal 102(7) 1646–1655
FIGURE 1 Quantitative evaluation of binding
of aS to DPPC-SUV. (A) 2D-FIDA histograms of
incubations of red-labeled monomeric aS in solu-
tion (aS-647, left panel), green-labeled (BODIPY-
PE) DPPC vesicles (DPPC-SUV, middle panel) in
solution, and a mixture aS and DPPC-SUV (right
panel). X axis, green fluorescence; Y axis, red
fluorescence. Excitation at 488 and 633 nm. (B)
1D-FIDA histograms of monomeric aS in solution
(left), DPPC-SUVin solution (middle), and vesicle-
bound aS (right). (C) Normalized autocorrelation
plots derived from FCS measurements of mono-
meric aS in solution, DPPC-SUV in solution, and
aS in the presence of DPPC-SUV. (In panels B
and C, red traces represent aS-647, green traces
represent BODIPY-PE fluorescence.)
1648 Ho¨gen et al.the average brightness of the detected particles. It should be
noted that a homogeneous population of vesicles with on
average four fluorophores per vesicle leads to a distribution
of intensity ranging from 0 to 250 photons/bin (Fig. 1 A,
middle panel). The detection of bins with high photon counts
in both the red and green channel demonstrates association of
aS to DPPC-SUV (Fig. 1 A, right panel). This could be
corroborated by quantitative FIDA evaluation of 1D-FIDA
histograms (Fig. 1 B), which can be used to calculate the
average brightness and concentration of the particles (see
Supporting Material and Kask et al. (55)).
For aS incubated with DPPC-SUV, there was a four- to
fivefold increase of red particle brightness, indicating that
~4–5 aS molecules bound per lipid vesicle (assuming that
the quantum yield of Alexa647 did not alter due to binding
of aS to the membrane). Furthermore, it could be calculated
that ~74% of the total amount of aS was bound to DPPC-Biophysical Journal 102(7) 1646–1655SUV in this assay (Table S1 in the Supporting Material).
In a different set of experiments using FCS, we first deter-
mined independently the diffusion times for unbound aS
(taS) and DPPC-SUV (tsuv). From the measured tsuv
(~6600 ms) we calculated a hydrodynamic radius of the
SUVof 34 nm, which matched the radius determined inde-
pendently with dynamic light scattering (see Supporting
Material). From the measured taS (~1000 ms) a hydrody-
namic radius for unbound monomeric aS of ~3 nm was
calculated, which also matches the expected value (61).
When aS was incubated in the presence of DPPC-SUV,
the autocorrelation of aS shifted dramatically toward the
curve of DPPC-SUV (Fig. 1 C). Because the diffusion
time of DPPC-SUV changes only marginally with a few
aS molecules bound to it (45), the fraction of bound aS
could be calculated by fitting the autocorrelation curve of
aS to taS and tsuv with a two-component fit (44). We found
FCS Study of Lipid Binding by Synuclein 1649that 83% of the total amount of aS was bound to DPPC-
SUV, which is in close agreement with the fraction bound
calculated from the FIDA data (Table S1).Aggregation of aS in the presence of vesicles
reveals two separate lipid-depending binding
modes
To investigate if there is a specific interaction between olig-
omeric species and lipid bilayers, we initially chose POPC-SUV to which monomeric aS has a low binding affinity
(5,34). When we incubated aS-647 with green-labeled
POPC-SUV, high-intensity bins could only be detected
along the X axis of the 2D-FIDA histogram (Fig. 2 B). These
bins are generated by POPC-SUV devoid of bound aS.
Unbound monomeric aS species generated bins close to
the origin of the FIDA histogram. Thus, as expected, mono-
meric aS did not bind to POPC-SUV under control buffer
conditions. Also, the addition of Fe3þ ions alone did not
cause any changes in the binding and aggregation of aS.FIGURE 2 Binding of aS to vesicles of different
lipid composition reveals two different binding
modes. (A) Scheme of the segments of a 2D-
FIDA histogram used for quantitative SIFT anal-
ysis. Data points in segments 1 and 2 are generated
by vesicles devoid of aS (‘‘purely green bins’’);
data points in segments 3–16 are caused by mono-
meric or aggregated aS bound to vesicles (‘‘dual
colored bins’’); and data points in segments 17
and 18 are caused by unbound aS aggregates
(‘‘purely red bins’’). Monomeric aS generates
data points only in the segment close to the origin.
The cartoons illustrate which type of particles
are detected: free vesicles with green labels
(green diamonds), free aS-monomers (red dots),
aS-aggregates, vesicles with bound aS-monomers,
or vesicles with bound aS-aggregates. (B) 2D-
FIDA histograms of incubations of POPC-SUV
and aS-647. (Top panels) Excitation at 488 and
633 nm. (Middle panels) FRET measurements
(excitation with 488 nm laser only). (Cartoons,
bottom row) The type of particles detected. (Panels
from the left to the right) Control experiments
(vesicles with aS), incubation with 10 mM FeCl3,
1% DMSO, and 1% DMSO þ 10 mM FeCl3,
respectively. (C) As panel B for DPPC-SUV. (D)
2D-FIDA histograms of LUV-POPC and LUV-
DPPC reveal that aS monomers do not bind to
these vesicles, whereas the DMSO/Fe3þ-induced
oligomers had a high binding propensity. (E) Quan-
titative FIDA analysis of panels B and C shows that
the average green particle brightness and concen-
tration of POPC- and DPPC-SUV is not altered
due to additions of iron and/or DMSO. (F) Average
red particle brightness of aS with and without
POPC-SUV under different aggregation condi-
tions. Q is the fitted brightness of aS monomers
in solution. Only with DMSO þ/ Fe3þ a second
population of aS aggregates with brightness Q2
was found in the data fit.
Biophysical Journal 102(7) 1646–1655
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of intermediate-I oligomers (4), as can be seen by the accu-
mulation of bins along the Y axis with higher red fluores-
cence intensity compared to aS monomers (Fig. 2 B).
However, the absence of bins with both green and red fluo-
rescence indicates that these intermediate-I oligomers were
not able to bind to the vesicles.
In contrast, under conditions generating intermediate-II
oligomers, i.e., in presence ofDMSOandFe3þ ions,we could
detect a significant formation of two-colored bins demon-
strating aS aggregates bound to POPC-SUV. Compared to
aggregation controls of aS in presence of DMSO and Fe3þ
ions in absence of lipid vesicles (see Fig. 3, upper-left panel),
that results in largeaS oligomers yielding high intensity fluo-
rescent bins along the Y axis (i.e., ‘‘purely red bins’’), in the
presence of POPC-SUV almost no purely red bins with
high fluorescent intensity, i.e., free intermediate-II oligo-
mers, could be detected. Thus, the intermediate-II oligomers
had all bound to the POPC-SUV. In contrast, a large number
of high intensity fluorescent bins along the X axis (i.e.,
‘‘purely green bins’’), representing vesicles devoid of bound
aS, were still detected (see also Fig. 3, POPC-SUV only).
These results are also confirmed by quantitative analysis
of the number of high-intensity bins in sectors 1–18 of the
FIDA histograms (Fig. 2 A and Fig. S1).
Based on our expectation that the interaction of mono-
meric aSwith a lipid membrane-water interface can strongly
modulate misfolding and aggregation, we repeated theFIGURE 3 Binding of preformed aS intermediate-II oligomers to
vesicles. (Upper lanes) 2D-FIDA histograms of incubations of vesicles
and aS. (Leftmost panel) aS in the absence of vesicles after 2 h incubation
with 1% DMSO þ 10 mM FeCl3 showing the formation of intermediate-II
aggregates. (Two middle panels) POPC-SUV and DPPC-SUV in solution,
respectively. (Two right panels) To the sample of the leftmost panel
(intermediate-II aggregates), an aliquot of POPC-SUV or DPPC-SUV
was added, respectively, and the SIFT measurement was repeated. All
aggregates had bound to the vesicles. (Middle lanes) FRET measurements
of the incubations depicted in the upper lanes. (Cartoons, lower panels) The
type of particles detected.
Biophysical Journal 102(7) 1646–1655aggregation assay in the presence of DPPC-SUV. In this
case two-colored bins representing vesicles with bound aS
were already observed without the addition of DMSO and/
or Fe3þ ions (Figs. 1 A and 2 C). Only very few purely green
bins could be detected, indicating that virtually all vesicles
had a few monomeric aS molecules bound. In contrast to the
POPC-SUV, formation of free intermediate-I oligomers in
the presence of 1% DMSO could not be detected. Even
addition of Fe3þ ions and 1% DMSO, i.e., intermediate-II
oligomer promoting conditions, did not alter the FIDA
histogram (Fig. 2 C and see Fig. S2). Finally, we performed
our aggregation assays with LUVs made of POPC and
DPPC. Due to the lower curvature of LUVs compared
to SUVs, we had previously found that monomeric aS
does not bind to DPPC-LUV (34). This was confirmed in
these experiments (Fig. 2 D). The DMSO/Fe3þ induced
Intermediate-II oligomers, however, bound with similar
affinity to both POPC-LUV and DPPC-LUV (Fig. 2 D).Binding of aS to lipid vesicles revealed
by single-particle FRET
To obtain information about the interaction between the
fluorophores attached to aS and the fluorophores attached
to the lipids of the vesicles, we used a fluorescence reso-
nance energy transfer (FRET) approach within our experi-
mental setup (51,62). The same aggregation assay and
confocal setup was used as above, but with excitation only
at 488 nm. Virtually no FRET signal was recorded under
any condition with POPC-SUV (Fig. 2 B). Even the gener-
ation of intermediate-II oligomers by DMSO and Fe3þ,
although bound to vesicles, did not generate a FRET signal.
These findings corroborate, first, that monomeric aS did not
bind to POPC-SUV, and second, that the interaction
between BODIPY-PE in the lipids and oligomeric aS-647
aggregates, bound to the vesicles, was too weak to allow
for FRET. In contrast, we could detect a significant FRET
signal for BODIPY-PE-labeled DPPC-SUV and aS-647
monomers under all conditions, suggesting a close distance
between the fluorophore of monomeric bound aS and the
BODIPY label of the lipids. Addition of DMSO and/or
Fe3þ did not alter the FRET signals (Fig. 2 C). This implies
that the binding mode of monomeric aS to DPPC-SUV was
not altered by the presence of DMSO and Fe3þ, i.e., that
aggregation of aS was prevented.Quantitative FIDA analysis of oligomer formation
by aS
2D-FIDA graphs show the full raw data of SIFT measure-
ments and allow unbiased detection of different particle
species, which differ in regard to brightness and ratio
of two fluorescently labeled components. These data can
be used for quantitative FIDA analysis, as described in
detail in the Supporting Material. Control experiments
FCS Study of Lipid Binding by Synuclein 1651demonstrated that the quantum yield of the used red and
green fluorophores did not change upon additions of iron,
DMSO, or SDS (Fig. S3). The average green particle bright-
ness and concentration of the POPC- and DPPC-SUV did
not differ in the various assay conditions (Fig. 2 E), showing
that the vesicles had not dissolved upon the additions of
DMSO and/or iron. Furthermore, binding of aS monomers
or oligomers to the membrane did not dissolve the vesicles.
The concentration of the green particles also matched the
number expected from the incubated lipid concentration
(10 mM) assuming ~4000 lipid molecules per SUV (as
expected for vesicles with a diameter of ~25 nm). The
brightness of the green particles corresponded to four
BODIPY fluorophores per vesicles, as expected.
Evaluation of the average red particle brightness and
concentration by fitting the FIDA data was also informative,
despite the heterogeneity of the size of the oligomers that
were formed in our aggregation assay. Apart from the mono-
mers, a second population of brighter particles could be
detected upon additions of DMSO þ/ Fe3þ in the absence
of lipid vesicles (control) and in the sample with POPC-
SUV (Fig. 2 F). The brightness of the monomers (Q1) was
always at ~27 kHz for aS alone or incubated with Fe3þ,
whereas in the presence of DMSO a second population
with Q2 of ~400 could be detected for both the control
and in the presence of POPC-SUV. Assuming that the
quantum yield of Alexa647 was not different in the aggre-
gates, the intermediate-I oligomers contained on average
Q2/Q1 ¼ 14 monomers. In the presence of DMSO/Fe3þ,
Q2 increased to ~1400 for the control and 1100 in the pres-
ence of POPC-SUV. The fraction of aggregated aS in latter
case was 13%, showing that despite oligomer formation the
majority of aS in the sample had remained monomeric. The
intermediate-II oligomers comprised ~40–50 monomers. A
remarkable difference between experiments without vesi-
cles and samples with vesicles was that in the absence of
vesicles, after the 2 h incubation with DMSO/Fe3þ, the
concentration of aS was <10% compared to t ¼ 0, whereas
almost no reduction occurred when vesicles had been
present. Apparently the vesicles provided a sink for aS
oligomers to bind to, preventing them from adsorbing to
the wall of the well. When the data fit was performed for
the case of DPPC-SUV, the particle brightness for vesicles
in the red channel (Q2) did not change upon addition of
DMSO and/or Fe3þ indicating that no aggregation occurred
when aS monomers were tightly bound to the vesicles.Binding of preformed oligomers to membranes
In a different set of experiments, we first allowed red-
fluorescent aS to aggregate for 2 h after addition of 1%
DMSO and 10 mM FeCl3. Upon a SIFT measurement of
the sample, formation of intermediate-II oligomers was con-
firmed along the Y axis of the FIDA histogram (Fig. 3).
Subsequently, green fluorescent POPC-SUVs were addedto the oligomers and the sample again subjected to SIFT
measurements. The FIDA histogram showed no free aggre-
gates along the Y axis anymore (Fig. 3). On the contrary,
bins with dual high red and green fluorescence intensities
were observed, implying that virtually all oligomers had
bound to the vesicles. In addition, a number of green bins
remained along the X axis, representing vesicles devoid of
bound aS. Similar results were obtained when DPPC-SUV
were added to the preformed intermediate-II oligomers,
showing that the oligomers—once formed—also had stably
bound to these membranes. The absence of FRET signals in
all incubation mixtures corroborated that oligomers (and no
monomers) had bound to the vesicles. Quantitative analysis
revealed that due to the 2 h preincubation of aS before the
addition of the vesicles, ~90% of the original amount of
aS was lost from the solution, probably because it had asso-
ciated with the wall of the well. The remaining oligomers
were still detectable by SIFT measurement due to their
high fluorescence intensity. The number of dual-color
high-intense particles, however, was drastically reduced.
Due to the low concentration of monomeric aS, signal of
monomers bound to DPPC-SUV was below the detection
limit in the SIFT and FRET measurements.Detection of detergent-resistant intermediate-II
oligomers
Toxic aS aggregates in PD patients, transgenic mouse and
cell culture models of PD have been reported to be resistant
to dissolution by detergents such as SDS (17,63,64). In
fact, 0.2% SDS efficiently blocked de novo formation of in-
termediate-I and intermediate-II oligomers in our in vitro
aggregation assay. However, once formed, intermediate-II
oligomerswere resistant to dissolution bySDSwhereas inter-
mediate-I oligomers completely dissolved (4). To evaluate
these features in the presence of vesicles, we added 0.2%
SDS after 2 h of incubation time towells containing aS, vesi-
cles, and DMSO/Fe3þ and repeated the SIFT measurements.
In the case of POPC-SUV, SDS dissolved the lipid vesicles
completely as expected. What remained were POPC/SDS
mixed micelles generating bins close to the origin of the
FIDA histogram, i.e., particles with much less BODIPY-
PE-labels per particle compared to the POPC-SUV
(Fig. 4 A). In addition, free SDS-resistant intermediate-II
oligomers with high fluorescence intensity could still be
detected along the Y axis. In the case of DPPC-SUV, SDS
also solubilized the vesicles (Fig. 4 B). However, compared
to the POPC-SUV, only signals at low photons/bin ratios
were detected along the Y axis, thus representing aS mono-
mers most likely bound to SDS/DPPC micelles. In contrast
to the case of POPC-SUV, no SDS-resistant oligomers
were detectable upon dissolution of the DPPC-SUV. These
findings further support our earlier conclusion that binding
of aS-monomers to DPPC membranes had prevented forma-
tion of DMSO/Fe3þ-induced aggregates.Biophysical Journal 102(7) 1646–1655
FIGURE 4 Solubilization of vesicles and aS
oligomers. 2D-FIDA histograms of incubations of
vesicles and aS aggregates. (A) POPC-SUV; (B)
DPPC-SUV. (Panels from the left to the right)
Vesicles with aS after 2 h incubation with 1%
DMSOþ 10 mM FeCl3, followed by solubilization
with 0.2% SDS, 10 mM Baicalein, or 10 mM
293GO2, respectively. SDS dissolved the vesicles;
Baicalein and 293GO2 dissolved the aS aggre-
gates. (Cartoons, lower panels) The type of parti-
cles detected.
1652 Ho¨gen et al.Aggregation inhibitors can dissolve membrane
bound intermediate-II oligomers
Compounds inhibiting aggregation of aS-monomers have
been identified in high throughput assays (4,17,65–73).
We added two potent inhibitors (Baicalein and 293G02)
after 2 h of incubation time to wells containing aS, vesicles,
and DMSO/Fe3þ and repeated the SIFT measurements. In
the case of POPC-SUV, vesicle-bound intermediate-II olig-
omers dissolved upon addition of the inhibitors, whereas
intact vesicles remained detectable along the X axis
(Fig. 4 A). The released aS monomers did not bind to the
POPC-SUV, as expected. In the case of DPPC-SUV, upon
addition of the inhibitors, the FIDA analysis displayed aS
monomers bound to vesicles, similar to the case before the
addition of the inhibitors (Fig. 4 B).DISCUSSION
The working hypothesis in many studies is that oligomeric
aggregation intermediates rather than mature amyloid fibrils
represent the principal toxic species in various neurodegen-
erative diseases. However, many issues remain unclear: 1),Biophysical Journal 102(7) 1646–1655Numerous different oligomer species, formed in vivo as
well as in vitro, have been described and it is not always
clear how they are formed (6,74). 2), In vivo probably
a heterogeneous population of aS oligomers coexists with
monomers and fibrils, and it is not clear which subfraction
of oligomer species is toxic. 3), The underlying molecular
events causing their neurotoxicity have not been completely
elucidated. Oligomers might bind to specific cytosolic
proteins, organelles, or membrane receptors, change their
function, or affect signaling pathways (6,75–77). Alterna-
tively, annular oligomers might insert into membranes and
make them leaky to ions (4,7,74,78,79). Whether the latter
occurs by a pore-forming mechanism (i.e., insertion of
protein aggregates into the membrane) or by some other
kind of membrane-damaging mechanism remains to be clar-
ified (4,74,80). In this study, association of the oligomers to
vesicles was strong and might have permeabilized the vesi-
cles but did not dissolve the vesicular structure. The latter
was only found when detergent was added (Figs. 2 E
and 4 A).
With regard to aS, studies on its aggregation are further
complicated by its structural flexibility. Whether lipid bind-
ing impedes or enhances its aggregation is controversial.
FCS Study of Lipid Binding by Synuclein 1653Using different techniques and various lipids, opposing con-
clusions were drawn (5,43,44,74,81–84). A high concentra-
tion of aS at the membrane surface and the hydrophobic
interface provided by the membrane might enhance aS clus-
tering and aggregation (12,85–87). Conversely, the a-helical
structure of membrane-bound aS might impede misfolding
to b-sheet-like conformers on pathway to fibrillar aS (88).
This article provides evidence that the latter is the case. In
this study, strong binding of aS to DPPC-SUV was quanti-
tatively evaluated (Fig. 1, Supporting Material) and was
consistent with other studies (33,34). The established struc-
tural switch of monomeric aS when it binds to lipid surfaces
seems to impede its aggregation (Fig. 2). In contrast, when
monomeric aS did not bind to lipids, i.e., in the presence of
POPC-SUV, at the vesicle concentration used, aggregation
of aS was not impeded (Fig. 2). The oligomers formed
subsequently had a high propensity to bind to the vesicles.
Traces of organic solvents induce generation of a partially
folded aS intermediates and accelerate amyloid formation
(12,74,89). We used this approach as a model system to
study aggregation pathways of aS in vitro at concentra-
tions in the nanomolar range, allowing efficient oligomer
characterization by confocal single particle fluorescence
techniques. Additionally, we reasoned that oligomeric aS
aggregation intermediates might be kinetically trapped, as
amyloid formation is highly inefficient at low aS concentra-
tions. Indeed, quantitative FIDA analyses of our aggregation
studies showed that, in the case of DMSO/Fe3þ, 87% of
aS remained as monomers. Addition of traces of organic
solvent lowers the dielectric constant of the buffer. The
latter favors hydrophobic interactions. It should be noted
that agitation, often used to accelerate aggregation, provides
hydrophobic-hydrophilic interfaces created by air bubbles
(85). Hence the driving force to accelerate aggregation by
agitation might be the same as by adding traces of organic
solvent. In light of the involvement of iron ions in the path-
ogenesis of PD we investigated the enhancement of aS
aggregation in the presence of Fe3þ ions (4,13). Because
of the very low solubility of Fe3þ and its association with
aS, Fe3þ might seed aS aggregation (26). In our assay,
Fe3þ alone did not enhance aggregation (Fig. 2, B and F).
This is at variance with other reports where much higher
aS and iron concentrations were used (13,25).CONCLUSION
Association of monomeric aS to lipids and concomitant
a-helical folding is a well-established binding mode. This
article establishes a second binding mode of specific
aS-oligomers formed in solution in the presence of Fe3þ.
Whereas binding of monomeric aS requires lipid surfaces
with negative charges and/or packing defects, binding
affinity of oligomers to membranes is high, regardless of
their lipid composition or curvature. The two different
binding modes could also be distinguished by FRET anal-ysis. Bound monomers had a detectable FRET signal
between the Alexa-647-labels of aS and the BODIPY-PE
incorporated into the membranes, despite the small spectral
overlap of the emission spectra of BODIPY-PE and the
excitation-spectra of Alexa-647. On the other hand, bound
oligomers displayed no detectable FRET signal. This is
probably due to the larger distance between the two labels
when oligomers are bound to the membranes and the
much slower lateral diffusion of the oligomers compared
to the monomers. Thus, despite the heterogeneity of the
oligomers, the different single-molecule fluorescence tech-
niques used in this study provided a powerful platform to
distinguish between the two lipid binding modes of aS.
Interestingly, membrane-bound oligomers readily dissolved
in the presence of aggregation inhibitors (Fig. 4). The
compounds neither dissolved the vesicles nor did they alter
the binding of monomeric aS to membranes. This makes
them an attractive tool for drug development in PD.SUPPORTING MATERIAL
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